sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_8469> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_8469> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00558> ;
    a rdf:Statement ;
    rdfs:label "relenza an influenza virus neuraminidase inhibitor nai is indicated for treatment of acute uncomplicated influenza type a and b infections 1 1 prophylaxis of influenza 1 2 important limitations of use not recommended for treatment or prophylaxis of influenza in 5 1 not proven effective for 1 3 1 3 not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 1 3 relenza zanamivir inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older see warnings and precautions 5 1" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00558> bl:category bl:Drug .
}